Hem/Onc News

Osimertinib Approved for First-Line Treatment in Metastatic NSCLC On April 18, the US Food and Drug Administration (FDA) approved osimertinib (Tagrisso, AstraZeneca) for the first-line treatment […]

Targeted Therapy for the Adjuvant Treatment of Stage III BRAF-Mutated Melanoma

H&O What is considered the standard adjuvant treatment for stage III BRAF-mutated melanoma? GL The standard treatment for patients with stage III BRAF-mutated melanoma after […]

In the Pipeline: Encorafenib and Binimetinib in BRAF-Mutated Melanoma

H&O What makes the BRAF inhibitor encorafenib plus the MEK inhibitor binimetinib a good combination for use in BRAF-mutated melanoma? KF Like other combinations of […]